受体酪氨酸激酶在骨肉瘤和尤文肉瘤中的作用

doi:10.3760/cma.j.issn.1673-422X.2015.07.021

摘要/Abstract

摘要： 骨肉瘤和尤文肉瘤是最常见的两种原发性恶性骨肿瘤。包括各种细胞生长因子和原癌基因产物在内的受体酪氨酸激酶类（RTK）是一种高亲和力的细胞表面受体，对于正常细胞发挥生理功能有着重要作用。研究已证明，异常的受体酪氨酸激酶信号传导通路有助于骨肉瘤和尤文肉瘤的发生和发展，包括肿瘤细胞的生存、增殖、侵袭和转移。针对受体酪氨酸激酶的靶向治疗是骨肉瘤和尤文肉瘤患者的前景性治疗方法。

关键词: 受体蛋白质酪氨酸激酶类, 骨肉瘤, 肉瘤, Ewing, 药物疗法

Abstract: Osteosarcoma and ewing sarcoma are the two most common types of primary malignant bone tumors. Receptor tyrosine kinases (RTKs), including varieties of cell growth factors and protooncogene products, are the highaffinity cell surface receptors which play an important role in the normal physiological function of cells. A large number of studies have demonstrated that the abnormal RTKs signaling pathways may promote the tumorigenesis and development of osteosarcoma and ewing sarcoma by affecting tumor cell survival, proliferation, invasion and metastasis. Targeting treatment of RTKs is a promising therapeutic approach for osteosarcoma and ewing sarcoma.

Key words: Receptor proteintyrosine kinases, Osteosarcoma, Sarcoma, Ewing′s, Drug therapy

沈国琪，张春林. 受体酪氨酸激酶在骨肉瘤和尤文肉瘤中的作用[J]. 国际肿瘤学杂志, 2015, 42(7): 551-553.

Shen Guoqi, Zhang Chunlin. Receptor tyrosine kinases in osteosarcoma and Ewing sarcoma[J]. Journal of International Oncology, 2015, 42(7): 551-553.

参考文献

［1］ Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma［J］. Pharmacol Ther, 2013, (2): 216-224. ［2］ Maniscalco L, Iussich S, Morello E, et al. Increased expression of insulinlike growth factor1 receptor is correlated with worse survival in canine appendicular osteosarcoma［J］. Vet J, 2014, In press. ［3］ Wang YH, Han XD, Qiu Y, et al. Increased expression of insulinlike growth factor1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma［J］. J Surg Oncol, 2012, 105(3): 235-243. ［4］ Scotlandi K, Manara MC, Serra M, et al. Expression of insulinlike growth factor system components in Ewing′s sarcoma and their association with survival［J］. Eur J Cancer, 2011, 47(8): 1258-1266. ［5］ Zhong H, Fazenbaker C, Breen S, et al. Medi573 alone or in combination with mammalian target of rapamycin inhibitors, targets the insulinlike growth factor pathway in sarcomas［J］. Mol Cancer Ther, 2014, 13(11): 2662-2273. ［6］ Bagatell R, Herzog CE, Trippett TM, et al. Pharmacokinetically guided phase 1 trial of the IGF1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors［J］.Clin Cancer Res, 2011, 17(3): 611-619. ［7］ Basu B, Olmos D, de Bono JS. Targeting IGF1R: throwing out the baby with the bathwater?［J］. Br J Cancer, 2011, 104(1): 1-3. ［8］ Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulinlike growth factor Ⅱ as additional treatment targets in human osteosarcoma［J］. Cancer Res, 2009, 69(6): 2443-2452. ［9］ Kuijjer ML, Peterse EF, van den Akker BE, et al. IR/IGF1R signaling as potential target for treatment of highgrade osteosarcoma［J］. BMC Cancer, 2013, 13: 245. ［10］ Puzanov I, Lindsay CR, Goff LW, et al. A phase Ⅰ study of continuous oral dosing of OSI906, a dual inhibitor of insulinlike growth factor1 and insulin receptors in patients with advanced solid tumors［J］.Clin Cancer Res, 2014, In press. ［11］ Fleuren ED, Roeffen MH, Leenders WP, et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas［J］. Int J Cancer, 2013, 133(2): 427-436. ［12］ Lin CH, Guo Y, Ghaffar S, et al. Dkk3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma［J］. Sarcoma, 2013, 2013: 147541. ［13］徐秋一, 牟海波, 徐农. 表皮生长因子受体酪氨酸激酶抑制剂的耐药机制及应对策略［J］. 国际肿瘤学杂志, 2012, 39(5): 355-359. ［14］ Chernoguz A, Crawford K, Donovan E, et al. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing′s sarcoma model［J］. J Surg Res, 2012, 173(1): 1-9. ［15］ Wang Q, Cai J, Wang J, et al. MiR143 inhibits EGFRsignalingdependent osteosarcoma invasion［J］. Tumour Biol, 2014, 35(12): 12743-12748. ［16］ Geng YD, Yang L, Zhang C, et al. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Ⅰ cariside Ⅱ results in reduced cell proliferation of osteosarcoma cells［J］. Food Chem Toxicol, 2014, 73: 7-16. ［17］ Sulzbacher I, Birner P, Dominkus M, et al. Expression of plateletderived growth factoralpha receptor in human osteosarcoma is not a predictor of outcome［J］. Pathology, 2010, 42(7): 664-668. ［18］ Bozzi F, Tamborini E, Negri T, et al. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors［J］. Cancer, 2007, 109(8): 1638-1645. ［19］ Takagi S, Takemoto A, Takami M, et al. Platelets promote osteosarcoma cell growth through activation of the plateletderived growth factor receptorAkt signaling axis［J］. Cancer Sci, 2014, 105(8): 983-988. ［20］ Wang YX, Mandal D, Wang S, et al. Inhibiting plateletderived growth factorbeta reduces Ewing′s sarcoma growth and metastasis in a novel orthotopic human xenograft model［J］. In Vivo, 2009, 23(6): 903-909. ［21］ Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy［J］. Curr Opin Oncol, 2013, 25(4): 398-406. ［22］ Miiji LN, Petrilli AS, Di Cesare S, et al. Ckit expression in human osteosarcoma and in vitro assays［J］. Int J Clin Exp Pathol, 2011, 4(8): 775-781. ［23］ Zhao H, Li M, Li L, et al. MiR133b is downregulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis［J］. PLoS One, 2013, 8(12): e83571. ［24］ Sampson ER, Martin BA, Morris AE, et al. The orally bioavailable met inhibitor PF2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model［J］. J Bone Miner Res, 2011, 26(6): 12831294. ［25］ Niswander LM, Kim SY. Stratifying osteosarcoma: minimizing and maximizing therapy［J］. Curr Oncol Rep, 2010, 12(4): 266-270.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[4]	姚昌菊, 朱治法, 张梅. 晚期腹膜后去分化脂肪肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 254-256.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	刘金立, 徐建利, 徐腾飞, 张玉杰, 辛晓文. 以凝血功能异常为首发表现的朗格汉斯细胞肉瘤1例[J]. 国际肿瘤学杂志, 2023, 50(9): 574-576.
[8]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[9]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	魏雪, 张万芳, 王尤, 刘苗苗, 周福祥. 心脏血管肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(4): 252-254.
[12]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[13]	马小平, 常君丽, 孙星媛, 杨燕萍. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54.
[14]	曹纯, 曾琴, 张天围. 头颈部滑膜肉瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 60-61.
[15]	张万芳, 王尤, 苏晶, 陈刚, 周福祥. 肺原发尤文肉瘤/原始神经外胚层瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 62-64.